AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04240496 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determination of plasma concentration of clozapine/ Genotyping
Description: Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 \& CYP2C19
Study NCT01662102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: Zevalin administered intravenously.
Study NCT01662102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab administered intravenously.
Study NCT01662102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously.
Study NCT00417417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
Study NCT00417417 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Normal saline subcutaneously at each treatment visit.
Study NCT01749332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perihepatic Phlebotomy
Study NCT02625857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041809 (Cohort 1A and 1B)
Description: JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\]) and at a higher dose in Cohort 1B (1x10\^9 CFU).
Study NCT02625857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041809 (Cohort 2A and 2B)
Description: JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
Study NCT02863419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral semaglutide once-daily.
Study NCT02863419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Subcutaneous (s.c.) injection once-daily.
Study NCT02863419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo once-daily.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part I - etoricoxib 60 mg
Description: etoricoxib 60 mg oral tablet once daily for 6 weeks
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part I - etoricoxib 90 mg
Description: etoricoxib 90 mg oral tablet once daily for 6 weeks
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part I- naproxen 1000 mg
Description: naproxen 500 mg oral tablet twice daily for 6 weeks
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part I - Placebo to naproxen 500 mg
Description: Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part II- etoricoxib 60 mg
Description: etoricoxib 60 mg oral tablet once daily for 20 weeks
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part II- etoricoxib 90 mg
Description: etoricoxib 90 mg oral tablet once daily for 20 weeks
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part II- naproxen 1000 mg
Description: naproxen 500 mg oral tablet twice daily for 20 weeks
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part I - Placebo to etoricoxib 60 mg
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part I - Placebo to etoricoxib 60 mg
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part I - Placebo to etoricoxib 90 mg
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part I - Placebo to etoricoxib 90 mg
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part II- Placebo to etoricoxib 60 mg
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part II- Placebo to etoricoxib 60 mg
Description: Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part II - Placebo to etoricoxib 90 mg
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part II - Placebo to etoricoxib 90 mg
Description: Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
Study NCT01208207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part II- Placebo to naproxen 500 mg
Description: Placebo to naproxen 500 mg orally twice daily for 20 weeks.
Study NCT01929746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 subcutaneous injection
Description: participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
Study NCT05021978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: 20 and 40 mg PRAX-944
Description: Once daily oral treatment
Study NCT05021978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: 120 mg PRAX-944
Description: Once daily oral treatment with titration
Study NCT05021978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part B: 120 mg PRAX-944 and Placebo
Description: Once daily oral treatment with titration followed by placebo
Study NCT01048619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
Study NCT03367988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthesia
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.
Study NCT03367988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-free Anesthesia
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluorodeoxyglucose
Study NCT00043979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: 6 mg/kg per dose orally every other day (no day 9 dose).
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Induction - 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m\^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Transplant - 100 mg/m\^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Induction - 60 mg/m\^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Initiated on day +3. Patients >40kg, the initial dose will be 2 mg every 24 hours orally. Patients \<40 kg, the initial dose will be 1 mg/m\^2.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Induction - 0.4 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
Study NCT00043979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
Study NCT00043979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT00043979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell donation
Study NCT04458870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
Study NCT04069702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Blue
Description: VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
Study NCT06316050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: humeral retroversion
Description: REVERSED SHOULDER ARTHROPLASTY IN TWO DIFFERENT GROUPS. Group 0 humeral retroversion, Group 30º humeral retroversion
Study NCT01495403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: daily dosing
Study NCT00930046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine wound catheter
Description: 19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
Study NCT00930046 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline wound catheter
Description: 19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
Study NCT02097264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
Study NCT02097264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
Study NCT02097264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
Study NCT02097264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
Study NCT01755182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: approved pharmacologic therapy
Study NCT01755182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: approved pharmacologic therapy
Study NCT01755182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAE
Description: after randomization, and after 3 months
Study NCT04572789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
Study NCT04572789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-6 PUFAs
Description: All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
Study NCT04600596 — intervention group
Intervention type: BEHAVIORAL
Intervention: Recording of food intake.
Description: The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.
Study NCT02130843 — intervention group
Intervention type: DEVICE
Intervention: INSERTION OF URETEHRL CATHETER
Description: USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
Study NCT01526577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC23-1306
Description: LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
Study NCT01526577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: LC23-1306 placebo
Study NCT01526577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg
Study NCT04198558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody
Study NCT04198558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02196844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: 5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
Study NCT02196844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
Study NCT02196844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk Test
Description: 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
Study NCT02694016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
Study NCT06367140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-triggered CIMCT device
Description: The study tested an EMG-triggered CIMCT device for stroke rehab, involving EMG sensors, a stationary bike, and a control unit displaying muscle activity. The protocol included warm-up, therapist-guided exercises, and cool-down, performed under supervision.
Study NCT06367140 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: general cycling training
Description: The training aimed to improve overall physical fitness and potentially aid in stroke recovery through regular cycling activity, conducted under supervision to ensure participant safety and adherence to the protocol.
Study NCT02987686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Infliximab
Description: Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Given orally
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given orally
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Description: Given IT